Blood Cancer
Blood cancer, or hematological malignancy / haematolymphoid tumors, encompasses a cluster of devastating diseases that wreak havoc on the delicate balance of the blood, lymphatic system, and bone marrow. Our team of scientists is steadfastly diving into the realm of preclinical research to meticulously evaluate the safety and efficacy of potential therapies for this rare disease.
What is Blood Cancer?
Blood cancer is a result of the uncontrolled growth and proliferation of abnormal blood cells, leading to the disruption of their normal functions. It can manifest in various forms, affecting different types of blood cells. Leukemias affects white blood cells, lymphomas affect lymphocytes, and myeloma affects plasma cells. These cancerous cells have the ability to infiltrate important tissues such as the bone marrow, lymph nodes, and other organs, which compromises the production of healthy blood cells and weakens the immune system.
Pathogenesis of Blood Cancer
The pathogenesis of blood cancer involves complex genetic and molecular alterations that drive the transformation of normal blood cells into cancerous ones. Mutations and abnormalities in genes responsible for regulating cell growth, division, and differentiation play a significant role in developing blood cancers. For example, the BCR-ABL fusion gene in chronic myeloid leukemia (CML) and the MYC oncogene in Burkitt lymphoma are key drivers of disease progression.
Fig.1 Causes and modes that underlie CCR7 overexpression in blood cancers. (Cuesta-Mateos, Carlos, et al., 2021)Classifications of Blood Cancer
Myeloid Proliferations and Neoplasms
Myeloid proliferations and neoplasms are a diverse group of disorders characterized by the clonal expansion of cells from the myeloid lineage. These disorders can manifest as acute or chronic conditions and encompass various subtypes, each with distinct molecular features.
Histiocytic / Dendritic Cell Neoplasms
Histiocytic and dendritic cell neoplasms represent a rare and heterogeneous group of disorders arising from cells of the mononuclear phagocyte system. These neoplasms can present as localized or disseminated diseases and include entities such as Langerhans cell histiocytosis, Erdheim-Chester disease, and histiocytic sarcoma.
B-cell Lymphoid Proliferations and Lymphomas
B-cell lymphoid proliferations and lymphomas encompass a wide spectrum of diseases, ranging from indolent to aggressive forms. The updated classification of these disorders incorporates advancements in genomic and molecular profiling, enabling more precise diagnosis and prognostication.
T-cell and NK-cell Lymphoid Proliferations and Lymphomas
T-cell and NK-cell lymphoid proliferations and lymphomas comprise a diverse group of disorders characterized by clonal expansion of cells from the T-cell or NK-cell lineage. The revised classification of these neoplasms takes into account their unique genetic and immunophenotypic profilesc.
Stroma-Derived Neoplasms of Lymphoid Tissues
Stroma-derived neoplasms of lymphoid tissues are a distinct group of tumors arising from non-hematopoietic cells within lymphoid organs. These neoplasms include entities such as follicular dendritic cell sarcoma and interdigitating dendritic cell sarcoma. The updated classification of these rare tumors incorporates molecular and genetic data, leading to refined therapy approaches.
Genetic Tumor Syndromes
Genetic tumor syndromes are hereditary conditions characterized by an increased predisposition to develop specific types of neoplasms. These syndromes result from germline mutations in key genes involved in DNA repair, cell cycle regulation, and tumor suppression. The identification of these genetic alterations has facilitated early detection and management strategies.
Our Services
Developing effective therapies for blood cancer requires a comprehensive understanding of the disease's biology and the identification of specific targets for intervention. Our company has a broad range of blood cancer research platforms, including diagnostics, small molecule drug, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. We employ a multidisciplinary approach to therapy development, combining cutting-edge technologies, advanced research methodologies, and a team of experienced scientists and researchers.
Types of Blood Cancer Research
- Myeloid Proliferations and Neoplasms
- Histiocytic / Dendritic Cell Neoplasms
- B-cell Lymphoid Proliferations and Lymphomas
- T-cell and NK-cell Lymphoid Proliferations and Lymphomas
- Stroma-derived Neoplasms of Lymphoid Tissues
- Genetic Tumor Syndromes
Our company is committed to supporting the development of effective therapies for blood cancer through our comprehensive range of services. We offer expertise in rare disease model studies, drug safety evaluation, and pharmacokinetic analysis, enabling us to bridge the gap between laboratory discoveries and applications. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Cuesta-Mateos, Carlos, Fernando Terrón, and Marco Herling. "CCR7 in Blood Cancers–Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target." Frontiers in Oncology 11 (2021): 736758.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
